Allspring Global Investments Holdings LLC Has $7.36 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Allspring Global Investments Holdings LLC increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 8.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,324 shares of the company’s stock after buying an additional 4,588 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.21% of Krystal Biotech worth $7,360,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. TimesSquare Capital Management LLC bought a new position in shares of Krystal Biotech during the third quarter valued at $14,272,000. Charles Schwab Investment Management Inc. grew its stake in Krystal Biotech by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company’s stock worth $20,854,000 after buying an additional 17,614 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Krystal Biotech by 40.7% during the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after buying an additional 693,852 shares in the last quarter. Trexquant Investment LP raised its stake in shares of Krystal Biotech by 8.8% in the third quarter. Trexquant Investment LP now owns 8,113 shares of the company’s stock valued at $941,000 after acquiring an additional 657 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Krystal Biotech by 2.0% in the 3rd quarter. Northern Trust Corp now owns 213,263 shares of the company’s stock worth $24,739,000 after acquiring an additional 4,129 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Trading Down 0.3 %

Shares of NASDAQ:KRYS opened at $169.64 on Thursday. Krystal Biotech, Inc. has a 1-year low of $82.09 and a 1-year high of $189.97. The stock has a market capitalization of $4.84 billion, a P/E ratio of 2,120.77 and a beta of 0.85. The business has a 50-day moving average price of $157.74 and a two-hundred day moving average price of $129.49.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same period last year, the firm earned ($1.25) earnings per share. As a group, equities analysts predict that Krystal Biotech, Inc. will post 1.61 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on KRYS. Guggenheim raised their price target on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Stifel Nicolaus reissued a “buy” rating and set a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $164.22.

Insider Buying and Selling at Krystal Biotech

In other news, CAO Kathryn Romano sold 2,500 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total value of $325,000.00. Following the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 2,500 shares of Krystal Biotech stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $130.00, for a total transaction of $325,000.00. Following the transaction, the chief accounting officer now directly owns 12,556 shares in the company, valued at approximately $1,632,280. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,587 shares of company stock worth $6,535,591. Insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).